Zyversa Therapeutics Inc reports results for the quarter ended in March - Earnings Summary

Zyversa Therapeutics

15/05/2024 16:41

* Zyversa Therapeutics Inc  ZVSA.OQ  reported a quarterly
adjusted
loss of $4.53​​ per share for the quarter ended in March.  The
mean expectation of two analysts for the quarter was for a loss
of $3.70 per share. Wall Street expected results to range from
$-5.40 to $-2.00 per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Zyversa Therapeutics Inc's reported EPS for the quarter
was a
loss of $4.53​.
    * The company reported a quarterly loss of $2.83 million.
    * Zyversa Therapeutics Inc shares had fallen by 29.5% this
quarter and lost 41.2% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 74.7%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for Zyversa
Therapeutics Inc is $70.00 
This summary was machine generated from LSEG data May 15 at
03:40 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2024      -3.70          -4.53          Missed
 Dec. 31 2023      -21.40         -1.37 hundred  Missed
 Sep. 30 2023      -56.00         -31.50         Beat